Guangzhou Jet Bio-Filtration (688026.SH) plans to participate in setting up an industry fund mainly investing in early and mid-stage biopharmaceutical projects.

Guangzhou Jet Bio-Filtration (688026.SH) announced that the company plans to use its own funds or raise funds to establish Guangzhou Zengcheng District Nante Biomedical Investment Partnership Enterprise (Limited Partnership) with Guangzhou Nanyue Aoyang Fund Management Co., Ltd. (referred to as "Nanyue Aoyang") and Guangzhou Nanyue Fund Group Co., Ltd. (referred to as "Nanyue Fund"). The partnership will primarily invest in early and mid-stage biomedical projects, including but not limited to: precision diagnostic reagents and IVD, gene testing, cell therapy, localization of high-end medical devices and materials research and development, smart healthcare and informatization, and medical services in the field of healthcare. The total planned investment for the establishment of the fund is RMB 50.01 million, with the company planning to subscribe for RMB 25 million as a limited partner, representing 49.99% of the subscribed capital.